ArticleActa pharmaceutica Sinica. B2019
Novel fluorescent probes of 10-hydroxyevodiamine: autophagy and apoptosis-inducing anticancer mechanisms.
Article in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Shikonin as a therapeutic agent in renal cell carcinoma: insights from TEK-related causal association with glaucoma.Frontiers in pharmacology · 2025Article
- Facile construction of dual-response super-resolution probes for tracking organelles dynamics.Exploration (Beijing, China) · 2024Article
- 4-Deoxy-Drug design, development and therapy · 2024Article
- Experimental and computational study on anti-gastric cancer activity and mechanism of evodiamine derivatives.Frontiers in pharmacology · 2024Article
- Article
- Ratiometric and discriminative visualization of autophagic processes with a novel dual-responded lysosome-specific fluorescent probe.Biomaterials research · 2023Article
- Natural-product-based fluorescent probes: recent advances and applications.RSC medicinal chemistry · 2023Review
- A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes.Acta pharmaceutica Sinica. B · 2022Article
- Symmetry dual functional pyrimidine-BODIPY probes for imaging targeting and activity study.Frontiers in chemistry · 2022Article
- A NIR fluorescent probe for Vanin-1 and its applications in imaging, kidney injury diagnosis, and the development of inhibitor.Acta pharmaceutica Sinica. B · 2022Article
- Peroxidase-mimicking evodiamine/indocyanine green nanoliposomes for multimodal imaging-guided theranostics for oral squamous cell carcinoma.Bioactive materials · 2021Article
- Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.Acta pharmaceutica Sinica. B · 2020Article
- Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer.ACS medicinal chemistry letters · 2020Article
- Cardioprotective Role of Melatonin in Acute Myocardial Infarction.Frontiers in physiology · 2020Review
- GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy.Acta pharmaceutica Sinica. B · 2019Article
- Aurone derivatives as Vps34 inhibitors that modulate autophagy.Acta pharmaceutica Sinica. B · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural product evodiamine and its derivatives represent a promising class of multi-target antitumor agents. However, the clinical development of these compounds has been hampered by a poor understanding of their antitumor mechanisms. To tackle this obstacle, herein, novel fluorescent probes were designed to elucidate the antitumor mode of action of 10-hydroxyevodiamine. This compound was proven to be distributed in the mitochondria and lysosomes and to act by autophagy and apoptosis mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.